The researchers for the “RENEWED: A follow-subsequent analysis of the Phase II RENEW trial evaluating opicinumab in acute optic neuritis” aimed to evaluate the long-term effects of opicinumab, an anti-LINGO-1 monoclonal antibody, as a potential remyelinating therapy for AON, a condition frequently associated with MS [184]. Here, LINGO1 is linked to myeloid sarcoma.